Short Interest in Structure Therapeutics Inc. (NASDAQ:GPCR) Expands By 5.8%

Structure Therapeutics Inc. (NASDAQ:GPCR) saw a significant growth in short interest in December. As of December 31st, there was short interest totalling 10,750,000 shares, a growth of 5.8% from the December 15th total of 10,160,000 shares. Currently, 19.8% of the shares of the company are short sold. Based on an average daily volume of 824,600 shares, the short-interest ratio is presently 13.0 days.

Analyst Ratings Changes

Several research analysts have recently commented on GPCR shares. Morgan Stanley initiated coverage on Structure Therapeutics in a research note on Monday, September 23rd. They issued an “overweight” rating and a $118.00 price objective on the stock. JMP Securities restated a “market outperform” rating and set a $91.00 target price on shares of Structure Therapeutics in a research note on Wednesday, December 18th. HC Wainwright reiterated a “buy” rating and issued a $80.00 price target on shares of Structure Therapeutics in a research report on Thursday, December 19th. Cantor Fitzgerald restated an “overweight” rating and set a $65.00 price objective on shares of Structure Therapeutics in a research report on Monday, September 23rd. Finally, Stifel Nicolaus assumed coverage on shares of Structure Therapeutics in a report on Wednesday, January 8th. They issued a “buy” rating and a $50.00 target price for the company. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $81.29.

Structure Therapeutics Stock Up 0.3 %

NASDAQ GPCR traded up $0.08 on Monday, reaching $27.06. The company had a trading volume of 846,835 shares, compared to its average volume of 770,004. The stock has a market capitalization of $1.55 billion, a PE ratio of -36.57 and a beta of -2.78. Structure Therapeutics has a 12 month low of $23.50 and a 12 month high of $62.74. The firm’s 50 day moving average price is $30.78 and its 200 day moving average price is $36.03.

Institutional Investors Weigh In On Structure Therapeutics

Several large investors have recently made changes to their positions in the company. GAMMA Investing LLC boosted its stake in Structure Therapeutics by 4,155.6% during the fourth quarter. GAMMA Investing LLC now owns 1,149 shares of the company’s stock valued at $31,000 after buying an additional 1,122 shares during the last quarter. Sandia Investment Management LP bought a new position in shares of Structure Therapeutics during the 2nd quarter valued at approximately $39,000. FNY Investment Advisers LLC purchased a new position in shares of Structure Therapeutics in the fourth quarter valued at $40,000. Assetmark Inc. increased its position in Structure Therapeutics by 120.0% in the third quarter. Assetmark Inc. now owns 1,318 shares of the company’s stock worth $58,000 after purchasing an additional 719 shares during the last quarter. Finally, Quarry LP purchased a new stake in Structure Therapeutics during the second quarter valued at $79,000. 91.78% of the stock is owned by institutional investors.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.